Search Results - "Heyde, Eyck"

Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany by Singh, Prianka, McDonald, Laura, Waldenberger, Daniela, Welslau, Manfred, Heyde, Eyck, Gauler, Thomas, Dietz, Andreas

“…Background In the Phase‐III clinical trial, CheckMate 141, nivolumab significantly improved survival versus standard of care in patients with…”
Get full text

FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world by Marschner, Norbert, Hegewisch‐Becker, Susanna, Reiser, Marcel, Heyde, Eyck, Bertram, Mathias, Hollerbach, Stephan H., Kreher, Stephan, Wolf, Thomas, Binninger, Adrian, Chiabudini, Marco, Kaiser‐Osterhues, Anja, Jänicke, Martina

“…There is no prospective, randomised head‐to‐head trial comparing first‐line FOLFIRINOX and gemcitabine/nab‐paclitaxel in advanced pancreatic cancer. We assess…”
Get full text

Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315) by Sebastian, Martin, Eberhardt, Wilfried E. E., Heyde, Eyck, Dörfel, Steffen, Wiegand, Jörg, Schiefer, Clemens, Losem, Christoph, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Kaiser‐Osterhues, Anja, Hipper, Annette, Dietel, Corinna, Bleckmann, Annalen, Benkelmann, Robin, Boesche, Michael, Grah, Christian, Müller, Annette, Griesinger, Frank, Thomas, Michael

“…Patients with lung cancer under treatment have been associated with a high risk of COVID‐19 infection and potentially worse outcome, but real‐world data on…”
Get full text

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR by Schulz, Felicitas, Hauch, Ulrich, Ketzler-Henkel, Sandra, von der Heyde, Eyck, Koenigsmann, Michael, Lauseker, Michael, Schulte, Nora, Germing, Ulrich

“…Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow failure often resulting in anemia…”
Get full text

P679: SPOTLIGHT ON THE REAL‐WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES by Franke, Georg‐Nikolaus, Loewe, Gunnar, Reiser, Marcel, Linde, Hartmut, Josting, Andreas, Von Der Heyde, Eyck, Weide, Rudolf, Tesch, Hans, Nusch, Arndt, Dengler, Jolanta, Jentsch‐Ullrich, Kathleen

Get full text

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial by Grohé, Christian, Wehler, Thomas, Henschke, Sven, Hammerschmidt, Stefan, Aulmann, Christoph, Krüger, Stefan, Dittrich, Ina, Schuette, Wolfgang, von der Heyde, Eyck, Hanson, Sven, Bajorat, Joerg, Kaiser, Rolf

“…e21149 Background: The identification of targetable molecular tumor markers in patients (pts) with NSCLC has increased significantly over the past decades and…”
Get full text

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315) by Sebastian, Martin, Eberhardt, Wilfried E.E., Hoffknecht, Petra, Metzenmacher, Martin, Wehler, Thomas, Kokowski, Konrad, Alt, Jürgen, Schütte, Wolfgang, Büttner, Reinhard, Heukamp, Lukas C., Stenzinger, Albrecht, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Dille, Stephanie, Hipper, Annette, Sandberg, Marlen, Weichert, Wilko, Groschek, Matthias, von der Heyde, Eyck, Rauh, Jacqueline, Dechow, Tobias, Thomas, Michael, Griesinger, Frank

“…•CRISP prospectively collected real-world data on advanced NSCLC and KRAS mutations.•Of 1039 patients, 39.5 % had KRAS mutations, 38.9 % of these were KRAS…”
Get full text

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations by Meyer, Oliver, Schlag, Rudolf, Stauch, Thomas, Fleischmann, Bastian, Reiser, Marcel, Kaempfe, Dietrich, Behlendorf, Timo, Welslau, Manfred, von der Heyde, Eyck, Dörfel, Steffen, Willy, Claudia, Stauch, Martina

Get full text

Comparison of TKI and CPI strategies as first-line treatment of patients with advanced renal cell carcinoma: Real-world outcome data from the German research platform CARAT by Goebell, Peter J., Boegemann, Martin, Nusch, Arnd, Grünwald, Viktor, Mueller, Lothar, von der Heyde, Eyck, Reichert, Dietmar, Martens, Uwe Marc, Lennartz, Carolin, Koska, Michaela, Jänicke, Martina, Potthoff, Karin, Marschner, Norbert, Grüllich, Carsten, Staehler, Michael D.

“…4528 Background: Immune checkpoint inhibitors (CPI), in combination with tyrosine kinase inhibitors (TKI) or with another CPI, expanded the therapeutic options…”
Get full text

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3rd Interim Analysis of the German Non-Interventional Trial RISA by Meyer, Oliver, Stauch, Martina, Kaempfe, Dietrich, Schlag, Rudolf, Reiser, Marcel, von der Heyde, Eyck, Josting, Andreas, Plath, Margarete, Ballerstädt, Nadine, Stark-Lorenzen, Petra, Matzdorff, Axel

“…Background:Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, characterized by increased platelet destruction and impaired platelet production…”
Get full text

Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices by Franke, Georg-Nikolaus, Loewe, Gunnar, Reiser, Marcel, Linde, Hartmut, Josting, Andreas, von der Heyde, Eyck, Platzbecker, Uwe, Weide, Rudolf, Tesch, Hans, Nusch, Arndt, Dengler, Jolanta, Jentsch-Ullrich, Kathleen

“…Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized centers whereas primary care for patients (pts) with CML is mainly…”
Get full text

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study by Koschmieder, Steffen, Schulte, Clemens, von der Heyde, Eyck, Busque, Lambert, Boyer-Perrard, Françoise, Devos, Timothy, Passamonti, Francesco, Zuurman, Mike W., Paley, Carole, Gilotti, Geralyn, Cheng, Wendy Y., Gao, Chi, Cheng, Mu, Wu, Melody, Duh, Mei Sheng, Harrison, Claire N.

“…▪ Introduction: Cytoreductive therapy such as hydroxyurea and interferon is recommended for high-risk polycythemia vera (PV) patients (pts) and is often used…”
Get full text

Retrospective Analysis of Treatment Pathways in Patients With BRAF V600E -mutant Metastatic Colorectal Carcinoma – MORSE CRC by GERGER, ARMIN, EISTERER, WOLFGANG, FUXIUS, STEFAN, BASTIAN, SARA, KOEBERLE, DIETER, WELSLAU, MANFRED, SANOYAN, DILARA AKHOUNDOVA, MAAS, CHRISTIAN, UHLIG, JENS, FENCHEL, KLAUS, GREIL, RICHARD, VON DER HEYDE, EYCK, AGOCS, GAËLLE RHYNER, WEIDE, RUDOLF, SCHWAGER, MONIKA, REICHENBACH, FRANK, MODEST, DOMINIK PAUL, FRITSCH, RALPH

Get full text

Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study by Stintzing, Sebastian, von der Heyde, Eyck, Wierecky, Jan, Bürkle, Dieter, Forstbauer, Helmut, Hübner, Gerdt, Schmidt, Burkhard, Schroeder, Jan, Distelrath, Andrea, Flum, Marion, Reichenbach, Frank, Arnold, Dirk, Fritsch, Ralph M, Gerger, Armin, Hegewisch-Becker, Susanna, Vogel, Arndt, Wagner, Anna Dorothea, Winder, Thomas, Koeberle, Dieter, Prager, Gerald W.

“…34 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is associated with a poor prognosis and limited clinical data. Based on results from the…”
Get full text

Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer by Stintzing, Sebastian, Hübner, Gerdt, Schröder, Jan, Forstbauer, Helmut, Kisro, Jens, Welslau, Manfred, Müller-Huesmann, Harald, Bürkle, Dieter, Krammer-Steiner, Beate, von der Heyde, Eyck, Reichenbach, Frank, Arnold, Dirk, Fritsch, Ralph M, Gerger, Armin, Hegewisch-Becker, Susanna, Vogel, Arndt, Wagner, Anna Dorothea, Winder, Thomas, Koeberle, Dieter, Prager, Gerald

“…e15584 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by a poor prognosis and limited clinical data. Based on results from…”
Get full text

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial by Koschmieder, Steffen, Isfort, Susanne, Schulte, Clemens, Jacobasch, Lutz, Geer, Thomas, Reiser, Marcel, Koenigsmann, Michael, Heinrich, Bernhard, Wehmeyer, Jürgen, von der Heyde, Eyck, Tesch, Hans, Gröschl, Benedikt, Bachhuber, Petra, Großer, Susanne, Pahl, Heike L.

“…  Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating disease‑related splenomegaly or symptoms in adults patients with…”
Get full text

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma – MORSECRC by Gerger, Armin, Eisterer, Wolfgang, Fuxius, Stefan, Bastian, Sara, Koeberle, Dieter, Welslau, Manfred, Sanoyan, Dilara Akhoundova, Maas, Christian, Uhlig, Jens, Fenchel, Klaus, Greil, Richard, Von Der Heyde, Eyck, Agocs, Gaëlle Rhyner, Weide, Rudolf, Schwager, Monika, Reichenbach, Frank, Modest, Dominik Paul, Fritsch, Ralph

“…Background/Aim: Metastatic colorectal cancer (mCRC) is a heterogeneous disease with distinct molecular subtypes. The BRAFV600E-mutation found in approximately…”
Get full text

HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany by Dietz, Andreas, Welslau, Manfred, Hahn, Dennis, Langer, Christine, Bockmühl, Ulrike, Müller-Huesmann, Harald, Busch, Chia-Jung, Riera-Knorrenschild, Jorge, Büntzel, Jens, Kubuschok, Boris, von der Grün, Jens, Gauler, Thomas Christoph, Waldenberger, Daniela, von der Heyde, Eyck

“…Abstract only 6532 Background: Nivolumab has demonstrated efficacy in clinical trials of recurrent or metastatic squamous cell carcinoma of the head and neck…”
Get full text

Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung) by Sebastian, Martin, Gröschel, Andreas, Gütz, Sylvia, Schulz, Holger, Müller-Huesmann, Harald, Liersch, Rüdiger, von der Heyde, Eyck, Wiegand, Jörg, Ukena, Dieter, Bargon, Joachim, Schütte, Wolfgang, Riera-Knorrenschild, Jorge, Fischer, Jürgen R., Griesinger, Frank, Allan, Victoria, Waldenberger, Daniela, Schumann, Christian

“…Nivolumab was the first immune checkpoint inhibitor approved for use in advanced non–small cell lung cancer (NSCLC). This noninterventional, prospective cohort…”
Get full text

Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung) by Sebastian, Martin, Gröschel, Andreas, Gütz, Sylvia, Schulz, Holger, Müller-Huesmann, Harald, Liersch, Rüdiger, von der Heyde, Eyck, Wiegand, Jörg, Ukena, Dieter, Bargon, Joachim, Schütte, Wolfgang, Riera-Knorrenschild, Jorge, Fischer, Jürgen R., Griesinger, Frank, Allan, Victoria, Waldenberger, Daniela, Schumann, Christian

“…Nivolumab was the first immune checkpoint inhibitor approved for use in advanced non–small cell lung cancer (NSCLC). This noninterventional, prospective cohort…”
Get full text